I have been out of the loop since Cramer said this is a $300 stock a few months ago. Does he still think so? He is too shrill, loud and boisterous for me to take so have not heard him in a long time. It seems that instead of heading to $300 as predicted by Cramer, The stock is going the other way, unless there was a stock split, which I think did not happen.
Agree. Much competition is coming next year. Some will be better, some may be way cheaper. India may copy it and ignore any patents. Time to be careful. Spread your bets among many wonderful biotech companies.
This news of the approval is old news. I just hope the stock does not go down based on the old adage buy on the rumor, sell on the news. Competition is coming and some wonder if the insurance companies will agree to pay this extortion price of over $85,000 per treatment.